MedPath

CANCER care in COVID-19 ERAâ?? A survey proposed to study the treatment preference and perspectives of patients with blood cancer in a highly specialized cancer care hospital in India during COVID-19 ERA.

Not Applicable
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
Registration Number
CTRI/2020/06/026039
Lead Sponsor
I
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients under evaluation for a suspected hematological malignancy or with a diagnosis of hematological malignancy (acute and chronic leukemias, lymphomas, myeloma, and others) will be included in the study.

2. Patients who are planned for or receiving chemotherapy / immunotherapy / targeted therapy in the OPD, ward, daycare and ICU will be eligible.

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients who plan to continue on full intensity therapy- This will be the percentage of patients who are willing to go ahead with the full intensity therapy in the current scenario.Timepoint: 6 months or till the end of pandemic
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath